Note: Descriptions are shown in the official language in which they were submitted.
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
1
Method for the Production of Nucleic Acids Consisting of Stochastically
Combined Parts of Source Nucleic Acids
The present invention relates to a method for the production of nucleic acids
con-
sisting of stochastically combined parts of source nucleic acids as well as to
a kit
for carrying out said method.
In nature, nucleic acids provide the biological information that determines
struc-
ture and function of proteins and, thereby, controls the entire functionality
of liv-
ing beings, from the simplest bacterial cell to very complex multi-cellular
organ-
isms. It has been shown, that proteins can be engineered to have new or
altered
properties that can be exploited for technical or medical purposes. Such engi-
neering can be done by modifying the nucleic acid sequence coding for the
corre-
sponding protein, expressing the protein by means of an expression system,
testing the protein properties by a sufficiently powerful screening technique
and
selecting those that are best performers. Of course, when nucleic acids serve
as
functional molecules themselves, this procedure can be employed as well.
Whenever the procedure is done in an iterative manner, the technique is termed
directed evolution by analogy to nature's way to generate new functions and
alter existing ones.
The modification of nucleic acids is an intrinsic step in directed evolution.
Besides
the introduction of punctual mutations, the recombination of sequence parts is
a
very successful strategy for modifying nucleic acids and for generating
diverse
libraries that can be subjected to screening and selection procedures
afterwards.
Sequence parts may be fragments of a genome, gene clusters, genes variants
within a gene cluster, parts of genes such as exons, or sequences coding for
do-
mains within a protein, but may also be very short nucleic acid fragments down
to few or even single nucleobases.
Recombination of parts of nucleic acids is preferably done by homologous recom-
bination. Homologous recombination is the combination of corresponding se-
quence parts from different source nucleic acids while maintaining orientation
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
2
and reading frame. Main advantage of homologous recombination is the preven-
tion of background noise of unrelated sequences that accompanies an unspecific
recombination.
Experimentally, homologous recombination is preferably done in vitro using
indi-
vidual enzymatic functions or defined mixtures or sequences of enzymatic proc-
essing steps.
A first in vitro method described in WO 95/22625 is PCR-based (see also Stem-
mer, Nature 370 (1994) 389). Here, overlapping gene fragments are provided
and are subsequently assembled into products of original length by a PCR
without
addition of primers. Thus, the mutual priming of the fragments in each PCR
cycle
allows for fragments of different origin to be incidentally linked to form a
product
molecule. Theoretically, recombination events introduced by this method are
sto-
chastically distributed over the whole resulting nucleic acid sequence. The
num-
ber of recombination events per nucleic acid molecule, i.e. the frequency of
re-
combination, and also the average distance between recombination sites is de-
termined by the fragment length. On the other hand, the minimal fragment size
is in the order of hundreds of base pairs in order to enable mutual priming at
a
sufficient rate. The shorter the fragments the lower is the probability of
efficient
annealing of fragments. Therefore, the number of recombination events per gene
is limited and, moreover, the minimal average distance of recombination sites
is
restricted. No means is provided to control these factors.
Another PCR-based method is described in WO 98/42728 (Shao et al., Nucl.
Acids Res. 26 (1998), 681). Here, primers with randomized sequences are used
which enable a start of polymerization at random positions within a polynucleo-
tide. Thus, similar to WO 95/22625, short polynucleotide fragments are formed
which can recombine with each other by mutual priming. With this method, con-
trolling the frequency and distance of the recombinations is hardly possible.
Moreover, unspecific primers lead to a comparatively high inherent error rate
which can constitute a problem with sensitive sequence parts and/or long
genes.
Another method described in WO 98/42728 uses a modified PCR protocol to pro-
yoke a strand exchange during the primer extension step in PCR (Zhao et al.,
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
3
Nat. Biotechnol. 16 (1998), 258). The method consists of priming template se-
quences with a primer followed by repeated cycles of denaturation and
extremely
abbreviated annealing and polymerase-catalyzed extension. In each cycle the
growing fragments can anneal to different templates based on sequence com-
plementarity and extend further. This is repeated until full-length sequences
form. Due to template switching, resulting polynucleotides can contain
sequence
information from different parental sequences. Accordingly, the recombination
frequency is controlled by the number of PCR cycles while the average distance
between recombination sites is determined by the actual setting of the
polymeri-
zation time. Due to technical limitations of provoking fast temperature
shifts, the
minimal average distance between recombination sites is in the range of
hundred
nucleobases.
WO 01/34835 describes a method for homologous recombination that is not PCR-
based. This method combines the controllability of the recombination frequency
with the possibility of regio-selective recombination. The method employs
partial
exonucleolytic single-strand degradation and template-directed single-strand
synthesis of double-stranded heteroduplices that are formed by melting and re-
annealing of source nucleic acids. Multiple. recombinations are achieved by re-
peating the degradation and re-synthesis steps in an iterative manner. Accord-
ingly, the number of cycles determines the recombination frequency. By control-
ling the exonucleolytic activity, the method allows for regioselective
recombina-
tion. Very short distances between recombination sites are practically only
achieved when focusing on a certain region in the range of hundred nucleobases
in the source nucleic acid molecules. Short average distances over the entire
source nucleic acid sequences are difficult to achieve.
Another method for homologous recombination that is not PCR-based is de-
scribed in WO 01/29211. The method relies on the ordering, trimming and
joining
of randomly cleaved parental DNA fragments annealed to a transient polynucleo-
tide scaffold. As for WO 95/22625, the minimal length of the generated frag-
ments is limited by the necessity of an efficient annealing to the template.
Therefore, the minimal distance between recombination sites is not below
several
hundred nucleobases.
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
4
Thus, the technical problem underlying the present invention is to provide a
method for the production of nucleic acids consisting of stochastically
combined parts
of source nucleic acids. Especially, the technical problem is to provide an in
vitro
homologous recombination method that allows the. targeted and defined
positioning of recombination sites. Several directed evolution experiments
have
shown the neccessity of executing homologous recombination in a controlled
fashion. For example, recombination of protein modules requires the
positioning
of recombination sites into a narrow range of the polynucleotide sequence.
Recombination of CDRs in an antibody requires the targeting of certain parts
of
the coding polynucleotide. Current recombination methods lack sufficient
controllability with respect to these factors. Therefore, targeting and
directing
should be possible with regard to the strand that is recombined, to the
position in
the sequence, and to the average distance between recombination sites. In
benefit of this, homologous in-vitro recombination would act as precisely as
it is
required for a number of directed evolution problems in a way that is not
achieved by the methods that are currently available.
Summary of the Invention
The.technical problem has been solved by providing the embodiments character-
ized in the claims. The present invention thus provides
(A) a method for the production of polynucleotide molecules with modified prop-
erties, comprising the following steps:
(1) providing a population of source nucleic acid molecules, the individual
nucleic acid molecules of said population having homologous and hetero-
logous segments and having at least one marker nucleotide incorporated
within its nucleic acid sequence;
(2) forming double-stranded polynucleotide molecules of the population
of source nucleic acid molecules provided according to step (1) compris-
ing double strands with heterologous segments (heteroduplices);
(3) producing single-stranded breaks at the incorporated marker nucleo-
tides of the double-stranded heteroduplices produced according to step
(2); and
(4) performing template-directed single-strand synthesis, with or without
incorporation of marker nucleotides starting from single-stranded breaks
produced according to step (3); and
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
(B) a kit for carrying out the method as defined in (A) above, preferably said
kit
containing at least one of the following components:
(i) marker nucleotides for incorporation in the polynucleotide molecules;
(ii) agents permitting the single-stranded breaks at the incorporated marker
nucleotides; and
(iii) buffers for carrying out the incorporation of the marker nucleotides and
pro-
ducing the single-stranded breaks at these sites.
In the method of embodiment (A) of the invention, in step (1) - if the source
nu-
cleic acid molecule is double stranded - the strands may be complementary or
partially complementary. Moreover, steps (3)-(4) may be carried out subse-
quently or contemporaneously. The following figures further explain the embodi-
ments of the invention. The figures are, however, not to be construed to limit
the
invention.
Short Description of the Figures
Figure 1: is a schematic illustration of the method of the invention.
Figure 2: illustrates the principle of the method using dUMP as the marker
nucleotide and employing UDG, a class II AP endonuclease and a
dRPase for the introduction of single-stranded breaks at the marker
nucleotides.
Figure 3: illustrates the principle of the method using dUMP as the marker
nucleotide and employing UDG, a class I AP endonuclease and a
class II AP endonuclease for the introduction of single-stranded
breaks at the marker nucleotides.
Figure 4: illustrates the principle of the method using dUMP as the marker
nucleotide and employing UDG, Endo VIII or Fpg, and a class II AP
endonuclease or a T4 polynucleotide kinase for the introduction of
single-stranded breaks at the marker nucleotides.
Figure 5: illustrates the principle of the method using rNMP as the marker nu-
cleotide and employing RNase H for the introduction of single-
stranded breaks at the marker nucleotides.
Figure 6: is a schematic illustration of the method of the invention employing
three cycles.
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
6
Figure 7: depicts a plasmid map of the shuttle vector pBV43 used in Example
3 of the Experimental Section, having the subtilisin gene inserted
behind the P43 promotor.
Figure 8: shows the mutations found in a representative set of recombinants
that was obtained by the method of the invention as described in
Example 3. The mutations are defined as differences in the amino
acid sequence when comparing the variants with the subtilisin wild
type amino acid sequence (SEQ ID N0:5). The amino acids are
abbreviated according to the one-letter codes as listed in Tablel. For
example, "E160D" means that Glutamic acid (abbreviated as E) at
position 160 of the wild type amino acid sequence is replaced by
Aspartic acid (abbreviated as D).
Figure 9: shows the results when performing the method of the invention for
three rounds with four different variants of the subtilisin gene from
Bacillus subtilis as described in Example 3. (A) Average number of
recombination events per gene; (B) Fraction of recombinants among
the resulting population. N is the number of clones in. each
experiment that was analyzed by sequence analysis. 1:1, 1:3 and
1:9 denote different ratios of the concentration of non-dUTP-
containing strands to the concentration of dUTP-containing strands
used in the method.
Detailed Description of the Invention
As set forth above, embodiment (A) of the invention relates to a method for
the
production of nucleic acids with modified properties, i.e., polynucleotides
con-
sisting of stochastically combined parts of the source nucleic acids. Said
embodi-
ment will be described in more detail with reference to figure 1, which
schemati-
cally shows a possible variant of the method of the invention.
Depending on the requirements, the method of the invention permits both an
incidental and a controlled new combination of heterologous sequence segments.
By adjusting the probability of incorporation of marker nucleotides the
average
distance between recombination sites can be controlled. Distances down to one
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
7
nucleotide are possible using appropriate ratios of nucleotides and marker nu-
cleotides. This is hardly achieved with any of the before mentioned methods.
In
addition, the frequency of recombination can be controlled in a wide range by
adjusting the number of cycles and the average recombination distance per cy-
cle. Such a control of the recombination frequency may also be achieved by
means of the method described in WO 01/34835 and the method described in
WO 98/42728 that relies on a PCR with strand exchange. It is at least in part
achieved by means of the methods described in WO 95/22625 and WO
01/29211. The method described in WO 98/42728 that relies on random priming
provides no means to control the recombination frequency.
Another aspect of methods for homologous recombination is their requirement
for a certain degree of homology between the source nucleic acids to be recom-
bined. The methods described in WO 95/22625, WO 98/42728 and WO 01/29211
all rely on the annealing of short sequence segments between the sites of re-
combination. In case that recombination events shall be distributed evenly
over
the entire nucleic acid sequence, this means that the entire source nucleic
acid
sequences have to provide sufficient homology to enable annealing of short nu-
cleic acid segments. Regions within the nucleic acid sequences with lower
homol-
ogy permit said annealing and accordingly interrupt the recombination
reaction.
In contrast, the method described in WO 01/34835 as well as the method of the
invention employ annealing of full length nucleic acid sequences to produce
het-
eroduplices which are subjected to the recombination process. Thereby, also re-
gions with rather low homology within the nucleic acid sequence do not
interrupt
the recombination and an overall lower homology is tolerated when compared to
the above mentioned methods.
Hence, the method of the invention is characterized by a combination of advan-
tages which could not be achieved with any of the methods disclosed so far.
Products resulting from each individual cycle according to the method of the
in-
vention are semi-conservative, single-stranded nucleic acid molecules, since -
depending on the embodiment - a longer or shorter sequence segment was
maintained at one side of the marker nucleotide incorporation site while the
se-
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
8
quence segment on the other side of the marker nucleotide incorporation site
was synthesized newly with the information of the template strand.
The term "marker nucleotides" in accordance with the present invention means
any nucleic acid monomer that is suited to be incorporated into a
polynucleotide
and that can be used as a marker to introduce single-stranded breaks at the
corresponding position in order to provide intramolecular starting points for
a
template-directed polymerization reaction. Preferably, marker nucleotides are'
analogous of standard nucleotides that can be recognized specifically by a
chemi-
cal reaction or by enzymatic treatment.
In a preferred embodiment, more than one cycle comprising the aforementioned
steps (1) to (4) is completed, i.e. at least two, preferably at least ten,
more pref-
erably at least twenty and most preferably at least fifty cycles. In this
embodi-
ment, the template directed single-strand synthesis in step (4) is done with
in-
corporation of marker nucleotides, thereby introducing in each cycle the
marker
nucleotides for the next cycle. Then, preferably, the last cycle is done
without
incorporation of marker nucleotides in order to produce double-strands free
from
marker nucleotides that can be processed further.
The cyclic application of the method of the invention makes it possible to
produce
nucleic acid molecules comprising multiple recombined sequence segments from
different source nucleic acids. In particular, the cyclic application makes it
possi-
ble to combine several heterologous sequence segments which each other.
Moreover, it is possible to control the recombination frequency for each
polynu-
cleotide strand by the number of cycles. With cyclic application, the average
dis-
tance between the new combinations can be controlled by the probability of in-
corporating marker nucleotides in each cycle.
In particular, the average distance between the starting points of the
template-
directed synthesis according to step (4) in each of two consecutive cycles is
con-
trolled by adjusting the probability of incorporating marker nucleotides in
step (4)
of the first of the two consecutive cycles. The probability of incorporating
marker
nucleotides can be controlled by adjusting the ratio of concentrations of
marker
nucleotides to standard nucleotides. Preferably, the probability of
incorporating
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
9
marker nucleotides is chosen to be lower than one and higher than the
reciprocal
of the length of the source nucleic acids in base pairs. It is noteworthy
that,
whenever more than one marker nucleotide is incorporated per polynucleotide
strand, only the marker nucleotide incorporated next to the starting point of
the
template-directed polymerization determines the distance between recombination
sites. All other marker nucleotides are removed without consequences (cf. Fig.
1).
In a preferred embodiment, the nucleic acid molecules in the . population of
source nucleic acid molecules provided according to step (1) are double
strands
and the marker nucleotides are incorporated within the nucleic acid sequence
in
both strands. Here, both strands are accessible for the production of single-
stranded breaks according to step (3) and, therefore, both strands are
subjected
to recombination and, at the same time, can serve as template strands.
In another preferred embodiment, the nucleic acid molecules in the population
of
source nucleic acid molecules provided according to step (1) are double
strands
and the marker nucleotides are incorporated within the nucleic acid sequence
in
only one of both strands (marker strand or sense strand). Accordingly, only
one
of both strands is accessible for the production of single-stranded breaks ac-
cording to step (3) and, therefore, only one of both strands is subject for
recom-
bination. The other strand serves only as a template during the whole process
(template strand or antisense strand).
In a particularly preferred embodiment, said double strands consisting of a
marker strand and a template strand are produced by PCR using one primer
having at least one marker nucleotide incorporated and a second primer without
having any marker nucleotides incorporated.
In another particularly preferred embodiment, said double strands consisting
of a
marker strand and a template strand are produced by annealing two single
strands, each of which is produced by asymmetric PCR using only one primer,
the
marker strand being produced with incorporation of marker nucleotides during
the polymerization step, while the template strand is produced without incorpo-
ration of marker nucleotides during the polymerization step.
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
In another preferred embodiment, the marker nucleotides incorporated in the
population of source nucleic acid molecules provided according to step (1) are
incorporated next to the 5'-end and the recombination site defined by the
incor-
poration site of marker nucleotides and the corresponding single-stranded
break
according to step (3) gets closer to the 3'-end of the polynucleotide
molecules
with increasing cycle number.
In another preferred embodiment, when more than one cycle is completed, the
probability of incorporating marker nucleotides is altered from cycle to
cycle. For
example, this can be done by altering the ratio of concentrations of marker nu-
cleotides and corresponding standard nucleotides. In this way, the distance be-
tween recombination sites can be controlled regioselectively.
The population of source nucleic acid molecules provided according to step (1)
of
the method of the invention can be any population of nucleic acid molecules
comprising at least two kinds of pol,ynucleotides, consisting of homologous
and
heterologous segments. Preferably, two of these polynucleotides each have at
least one homologous and two heterologous sequence segments when compared
with each other. The term "population of nucleic acid molecules" refers to any
kind of nucleic acid, e.g. single-stranded DNA, double-stranded DNA, single-
stranded RNA, double-stranded RNA, double-stranded hybrids of DNA and RNA,
or mixtures of any of these. In principle, the method may also be used for
simi-
larly constructed, artificial polymers. The term "homologous segments" denotes
segments which are identical or complementary on two or more nucleic acid
molecules, i.e. which have the same information at corresponding positions.
The
term "heterologous segments" means segments which are not identical or com-
plementary on two or more nucleic acid molecules, i.e. which have different in-
formation at corresponding positions. The term "information" or "genotype" of
a
nucleic acid molecule is the sequential order of various monomers in a nucleic
acid molecule. A heterologous sequence segment has preferably a length of at
least one nucleotide, but may also be much longer. For example, a heterologous
sequence segment may have a length of two nucleotides or three nucleotides,
e.g. a codon. In principle, there is no upper limit as regards the length of
the
heterologous segment. Nevertheless, the length of a heterologous segment
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
11
should not exceed 1,000 nucleotides, preferably it should not be longer than
500
nucleotides, more preferably not longer than 200 nucleotides and most prefera-
bly not longer than 100 nucleotides. Such longer sequence segments may, for
example, be the hypervariable regions of a sequence encoding an antibody, do-
mains of a protein, genes in a gene cluster, regions of a genome, etc.
Preferably,
the heterologous segments are sequence segments in which the nucleic acid
molecules differ in single bases. Heterologous segments, however, may also be
based on the fact that a deletion, duplication, insertion, inversion, addition
or
similar is present or has occurred in a nucleic acid molecule. .
According to the invention, the nucleic acid molecules provided according to
step
(1) of embodiment (A) have preferably at least one homologous and at least two
heterologous sequence segments. More preferably, however, they have a plural-
ity of homologous and heterologous segments. In principle, there is no upper
limit to the number of homologous and heterologous segments. A population of
source nucleic acid molecules according to the invention may consist of (i)
gene
variants each carrying one or more point mutations at various positions, or
(ii) of
gene homologous obtained from different species providing sufFcient homology
to produce - at least partially - heteroduplices, or (iii) of gene variants
each car-
rying one or more randomized cassettes such as antibody gene libraries. This
enumeration is, however, not to be construed to limit the invention.
The heterologous segments in the population of nucleic acid molecules provided
according to step (1) of the method are each interrupted by homologous seg-
ments. The homologous segments preferably have a length of at least 5, more
preferably of at least 10 and most preferably of at least 20 nucleotides. Like
the
heterologous segments, the homologous segments, too, may be much longer
and, in principle, there is no upper limit to their length. Preferably, their
length
should not exceed 5,000 nucleotides, more preferably not longer than 2,000 nu-
cleotides and most preferably not longer than 1,000 nucleotides.
In a particularly preferred embodiment of the method of the invention related
nucleic acid sequences are used for providing a population of source nucleic
acid
molecules according to step (1). In this context, the term "related" means
polynucleotides which have both homologous and heterologous segments among
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
12
each other. Related nucleic acid molecules may originate from a procedure to
introduce random point mutations into a source nucleic acid sequence. This in-
troduction of point mutations can be achieved by the inherent erroneous
copying
process alone, but also by the purposeful increase of the inaccuracy of the
poly-
merise used (e.g. by defined non-balanced addition of the monomers, by addi-
tion of base analogues, by error-prone PCR, by polymerises with very high
error
rate), by chemical modification of polynucleotides after synthesis, by the com-
plete synthesis of polynucleotides under at least partial application of
monomer
mixtures and/or of nucleotide analogues, by erroneous replication in vivo
(e.g.
by viruses having high error rates, by bacterial mutafor strains, by bacteria
under
UV irradiation, etc.), as well as by a combination of two or more of these
meth-
ods. Related nucleic acid molecules may also be nucleic acid molecules, that
have
been subjected to an alternative nucleic acid variation method, such as the
ran-
dom truncation, insertion, deletion or inversion of sequence segments or the
in-
troduction of randomized sequence segments. Related nucleic acid molecules
may also be nucleic acid sequences of the distribution of mutants of a quasi-
spe-
cies. A "quasi-species" is a dynamic population of related molecule variants
(mutants) which is formed by faulty replication and subsequent selection (WO
92/18645). Alternatively, related nucleic acid molecules may be nucleic acid
se-
quences isolated from natural sources that have a sufficient degree of
homology
to form heteroduplices according to step (2) of the method. For example, analo-
gous genes or gene fragments isolated from genomes of evolutionary related
species can be employed. Any of these related nucleic acid molecules may be
used directly or be subjected to a screening and/or selection procedure before
application of the recombination procedure, the selection and/or screening pro-
cedure selecting those nucleic acid molecules that have a certain phenotype.
The
term "phenotype of a nucleic acid molecule" denotes the sum of functions and
properties of the nucleic acid molecule and of the transcription or
translation
products encoded by the nucleic acid molecule.
The incorporation of marker nucleotides according to step (1) and, where appli-
cable, according to step (4) is achieved by using a template directed
polymerise
reaction or by chemical synthesis of oligonucleotides. Preferably, the
incorpora-
tion of marker nucleotides according to step (4) is done by using a template-
di-
rected polymerise reaction.
CA 02455325 2004-O1-27
WO 03/012100 PCT/ EP02/08122
13
For said template-directed polymerise reaction according to step (4) of the
method any enzyme with template directed polynucleotide-polymerization activ-
ity can be used which is able to polymerize polynucleotide strands starting
from
the 3'-end. A vast number of polymerises from the most varied organisms and
with different functions have already been isolated and described. With regard
to
the kind of the template and the synthesized polynucleotide, a differentiation
is
made between DNA-dependent DNA polymerises, RNA-dependent DNA poly-
merises (reverse transcriptases), DNA-dependent RNA polymerises and RNA-
dependent RNA polymerises (replicases). With regard to temperature stability,
a
differentiation is made between non-thermostable (37°C) and
thermostable po-
lymerises (75-95°C). In addition, polymerises differ with regard to the
presence
of 5'-3'- and 3'-5'-exonucleolytic activity.
When both, the template strand and the marker strand consist of DNA, DNA-de-
pendent DNA polymerises are preferably used. In particular, DNA polymerises
with a temperature optimum of exactly or around 37°C are used. These
include,
for instance, DNA polymerise I from E. coli, T7 DNA polymerise from the bacte-
riophage T7 and T4 DNA polymerise from the bacteriophage T4 which are each
traded by a large number of manufacturers. The DNA polymerise I from E. coli
(holoenzyme) has a 5'-3' polymerise activity, a 3'-5' proofreading exonuclease
activity and a 5'-3' exonuclease activity. The enzyme is used for in vitro
labeling
of DNA by means of the nick-translation method (J. Mol. Biol. 113 (1977), 237-
251). In contrast to the holoenzyme, the Klenow fragment of DNA polymerise I
from E. coli does not have a 5'-exonuclease activity, just like the T7 DNA
poly-
merise and the T4 DNA polymerise. Therefore, these enzymes are used for so-
called filling-in reactions or for the synthesis of long strands (Biochemistry
31
(1992), 8675-8690, Methods Enzymol. 29 (1974), 46-53). The 3'-exo(-) variant
of the Klenow fragment of DNA polymerise I from E. coli does not have the 3'-
exonuclease activity. This enzyme is often used for DNA sequencing according
to
Singer (Proc. Natl. Acid. Sci. USA 74 (1977), 5463-5467). Apart from these en-
zymes, there is a plurality of other 37°C DNA polymerises with
different proper-
ties which can be employed in the method of the invention.
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
14
Moreover, thermostable DNA polymerises can be used for the method of the in-
vention. Preferably, the most widespread thermostable DNA polymerise that has
a temperature optimum of 75°C and is still sufficiently stable at
95°C, the Taq
DNA polymerise from Thermus aquaticus, can be used. Taq DNA polymerise is
commercially available from various manufacturers. Taq DNA polymerise is a
highly-processive DNA polymerise without 3'-exonuclease activity. It is often
used for standard PCRs, for sequencing reactions and for mutagenic PCRs (PCR
Methods Appl. 3 (1994), 136-140, Methods Mol. Biol. 23 (1993), 109-114). How-
ever, several other thermostable DNA polymerises can be employed. The Tth
DNA polymerise from Thermus thermophilus HB8 and the Tfl DNA polymerise
from Thermus flavus have similar properties. The Tth DNA polymerise addition-
ally has an intrinsic reverse transcriptase (RT) activity in the presence of
manga-
nese ions (Biotechniques 17 (1994), 1034-1036). Among the thermostable DNA
polymerises without 5'- but with 3'-exonuclease activity, numerous of them are
commerically available: Pwo DNA potymerase from Pyrococcus woesei, Tli, Vent
or DeepVent DNA polymerise from Thermococcus litoralis, Pfx or Pfu DNA poly-
merise from Pyrococcus furiosus, Tub DNA polymerise from Thermus ubiqui-
tous, Tma or UITma DNA polymerise from Thermotoga maritima. Polymerises
without 3'-proofreading exonuclease activity are used for amplifying PCR prod-
ucts that are as free from defects as possible. With the Stoffel fragment of
Taq
DNA polymerise, with Vent-(exo-) DNA polymerise and Tsp DNA polymerise
thermostable DNA polymerises without 5'- and without 3'-exonucleolytic
activity
are available.
When RNA is used as the template strand nucleic acid and DNA as the marker
strand nucleic acid, RNA-dependent DNA polymerises (reverse transcriptases)
can be employed. Among the reverse transcriptases, preferably, the AMV reverse
transcriptase from the avian myeloblastosis virus, the M-MuLV reverse tran-
scriptase from the Moloney murine leukemia virus or the HIV reverse transcrip-
tase from the human immunodeficiency virus is .used. All three enzymes are
traded by various manufacturers. Like the HIV reverse transcriptase, the AMV
reverse transcriptase has an associated RNase-H activity. This activity is
signifi-
cantly reduced in M-MuLV reverse transcriptase. Both the M-MuLV and the AMV
reverse transcriptase do not have a 3'-exonuclease activity. Furthermore, a
thermostable reverse transcriptase can be used. Then the Tth-DNA polymerise
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
from Thermus thermophilus with intrinsic reverse transcriptase activity is par-
ticularly preferred.
When DNA is used as the template strand nucleic acid and RNA as the marker
strand nucleic acid, DNA-dependent RNA polymerises may be employed. Pref-
erably, the RNA polymerise from E. coli, the SP6-RNA polymerise from Salmo-
nella typhimurium LT2 infected with the bacteriophage SP6, the T3-RNA poly-
merise from the bacteriophage T3 or the T7-RNA polymerise T7 from the bacte-
riophage T7 is used.
In a preferred embodiment of the method, DNA is used as nucleic acid and de-
oxyuridine triphosphate (dUTP) is used as the marker nucleotide. Here, the in-
corporation of marker nucleotides according to step (1) and, where applicable,
according to step (4) is achieved- by using dUTP in combination with the four
standard deoxynucleoside triphosphates (dNTPs; deoxyadenosine triphosphate,
dATP; deoxyguanosine triphosphate, dGTP; deoxythymidine triphospiiate, dTTP;
deoxycytidine triphosphate, dCTP) in the template-directed polymerise
reaction.
The ratio of the dUTP to the dTTP concentration in this reaction can be chosen
in
a wide range in order to control marker nucleotide incorporation probability
and,
thereby, control the recombination distances. The exact ratio has to be
adapted
to the discrimination rate between dTTP and dUTP of the polymerise used in the
template-directed polymerise reaction as well as to the desired average
distance
between recombination sites. The discrimination rates between dTTP and dUTP
for a few of the aforementioned polymerises are: Taq DNA polymerise (Vrt,ax~Km
for the incorporation of dTTP) / (VmaX/Km for the incorporation of dUTP) =
1.2;
Klenow DNA polymerise = 1.6; Vent DNA polymerise = 1.4; MMLV reverse
transcriptase = 6.3 (J. Biol. Chem. 275 (2000) 40266). As an example, when Taq
DNA polymerise from Thermus aquaticus is used and average distances in the
range of 20 to 60 nucleobases are desired, the concentration ratio of dTTP to
dUTP should, preferably, be lower than 100,000 and be higher than 0.001. More
preferably the ratio should be lower than 1,000 and be higher than 0.1. Most
preferably, the concentration ratio of dTTP to dUTP should be in the range of
10.
In another preferred embodiment the nucleic acids used are DNA and 8-oxo-de-
oxyguanosine triphosphate (8-oxo-dGTP) is used as the marker nucleotide in
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
16
combination with the four standard dNTPs in the template directed polymerise
reaction. The marker incorporation probability and, thereby, the distance be-
tween recombination sites can be controlled by chosing an appropriate concen-
tration ratio between 8-oxo-dGTP and dGTP. As an example, when Taq DNA po-
lymerise from Thermus aquaticus is used and average distances in the range of
20 to 60 nucleobases are desired, the concentration ratio of 8-oxo-dGTP to
dGTP
in this reaction should preferably be chosen between 100,000 and 10. More pref-
erably, the concentration ratio should be chosen between 10,000 and 100. Most
preferably, the concentration ratio should be in the range of 1,000.
In another preferred embodiment marker nucleotides with one of the following
modified bases are used in combination with the four standard dNTPs in the tem-
plate directed polymerise reaction: 3-methyladenine, 7-methyladenine, 3-me-
thylguanine, 7-methylguanine, 7-hydroxyethylguanine, 7-chloroethylguanine,
02-alkylthymine, 02-alkylcytosine, 5-fluorouracil, 2,5-amino-5-formami-
dopyrimidine, 4,6-diamino-5-formamidopyrimidine, 2,6-diamino-4-hydroxy-5-
formamidopyrimidine, 5-hydroxycytosine, 5,6-dihydrothymine, 5-hydroxy-5,6-
dihydrothymine, thymine glycol, uracil glycol, isodialuric acid, alloxan, 5,6-
dihy-
drouracil, 5-hydroxy-5,6-dihydrouracil, 5-hydroxyuracil, 5-formyluracil, 5-hy-
droxymethyluracil, hypoxanthine, 1,N6-ethenoadenine, or 3,N4-ethenocytosine.
For the polymerise reaction any enzyme with template directed polynucleotide-
polymerization activity can be used which is able to incorporate these marker
nucleotides.
In another preferred embodiment the marker strand nucleic acid is DNA, and
one, two, three or all four ribonucleoside triphosphates (rNTPs) are used in
com-
bination with the four standard dNTPs in the template directed polymerise reac-
tion. The concentration ratio of the rNTP to the corresponding dNTP in this
reac-
tion can be used to control the marker incorporation probability and, thereby,
the
distance between recombination sites. Discrimination ratios (Vmax/Km for the
in-
corporation of dNTP) / (Vmax/Km for the incorporation of rNTP) for Taq DNA
poly-
merise are: dUTP/rUTP = 1,500,000, dCTP/rCTP = 24,000; for Klenow DNA po-
lymerise: dUTP/rUTP = 130,000, dCTP/rCTP = 3,100; for Vent DNA polymerise:
dUTP/rUTP = 10,000, dCTP/rCTP = 2,000; and for MMLV reverse transcriptase:
dUTP/rUTP = 21,000, dCTP/rCTP = 1,100 (J. Biol. Chem. 275, (2000) 40266). As
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
17
an example, when Vent DNA polymerase is used in combination with rCTP as the
marker nucleotide, and average distances in the range of 20 to 60 nucleobases
are desired, the concentration ratio of rCTP to dCTP should preferably be
lower
than 10,000 and higher than 1. More preferably, the ratio should be lower than
1,000 and higher than 10. Most preferably the ratio should be in the range of
100.
The formation of double-stranded heteroduplices according to step (2) of the
method of the invention is preferably achieved by hybridization of the homolo-
gous segments of the source nucleic acid molecules. The term "heteroduplices"
means double strands with at least one homologous and at least two heterolo-
gous segments. By using a population of nucleic acid sequences with heterolo-
gous segments, heteroduplices are formed with a statistical probability which
corresponds to the relative frequency of sequence variants in the population.
Starting out, for example, from an equimolar mixture of two variants having
two
heterologous segments, a heteroduplex statistically occurs with every second
double-stranded nucleic acid. If the number of variants is markedly higher
than
the relative frequency of individual variants, heteroduplices are formed
almost
exclusively.
Hybridization of homologous segments of the source nucleic acids to form het-
eroduplices is carried out according to methods known to the person skilled in
the art. In a preferred embodiment the source nucleic acid molecules are
single-
stranded and the hybridization is achieved by combining said single strands
and
adjusting reaction conditions which promote the annealing of homologous
nucleic
acids, e.g. by lowering of the temperature or adjusting the salt
concentration. In
another preferred embodiment, the source nucleic acid molecules are double-
stranded and the hybridization is achieved by melting the .double strands
under
appropriate conditions, e.g. at temperatures higher than the melting
temperature
of the double strand, and allow the strands to re-anneal, e.g. by lowering the
temperature below the melting temperature of the double strand.
The production of single-stranded breaks at the positions of incorporated
marker
nucleotides according to step (3) of the invention is preferably achieved by
chemical or enzymatic reactions. The term "breaks" means nicks or gaps in a nu-
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
18
cleic acid strand that can serve as starting points for a template-directed
poly-
merase reaction.
In a preferred embodiment, the single-stranded break is achieved by removing
the marker nucleotide by the action of one or more enzymes leading to a single
nucleotide gap and a free 3'-OH residue on the 5' side of said gap, the free
3'-OH
being extendable by a polymerase according to step (4) of the method.
In a particularly preferred embodiment, when DNA is the nucleic acid and dUTP
is
used as marker nucleotide, the uracil base of the incorporated marker uridine
residues is separated from the ribose by action of an uracil-DNA glycosylase
(UDG, Figures 2 - 4). A large number of different UDGs isolated from various
species has been described (Rev. Biochem. Tox. 9 (1988) 69; Mutat. Res. 460
(2000) 165). UDGs are involved in a base-excision pathway initiated by deami-
nation of the DNA base cytosine leading to uracil or by misincorporation of
uridine during DNA replication. The use of UDGs in PCR-carry-over-prevention
has been described (Gene 93 (1990) 125). UDG from E. coli is commercially
available in the engineered and in the non-engineered form by various manufac-
turers. ,E. coli UDG efficiently hydrolyzes uracil from single-stranded or
double-
stranded DNA, but not from dUTP. The minimal substrate for UDG was found to
be pd(UN)p (Biochemistry 30 (1991) 4055). The reaction can be started e.g. by
changing the buffer conditions or the temperature or by adding the UDG, and
can
be stopped, for instance, by changing the buffer conditions or the temperature
or
by adding an UDG inhibitor. The separation of the uracil bases from DNA con-
taining uridine residues results in apyrimidinic sites (AP sites).
In another particularly preferred embodiment, when DNA is the nucleic acid and
8-oxo-dGTP is used as marker nucleotide, the 8-oxo-guanine base is separated
from the ribose using formamidopyrimidine-DNA glycosylases (Fpg) (EMBO J. 6
(1987) 3177). The reaction can be started e.g. by changing the buffer
conditions
or the temperature or by adding the enzyme and can be stopped, for instance,
by changing the buffer conditions or temperature or by adding an inhibitor. In
addition to its formamidopyrimidine-glycosylase activity, this protein also
has a
nicking activity that cleaves via a a,f3-elimination both the 5'- and 3'-
phosphodi-
ester bonds at an AP site (Biochem. J. 262 (1989) 581). Thus the treatment of
a
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
19
polynucleotide molecule containing the 8-oxo-GMP residues leads to gaps of a
single nucleotide with a phosphate group both at the 5'- and 3'-end.
In another particularly preferred embodiment any other DNA N-glycosylase which
detects one of the aforementioned modified bases is employed. E. coli
alkylbase-
DNA glycosylase (alkA gene product, Mol. Gen. Genet. 197 (1984) 368), for
example, separates the bases from 3-methyladenosine, 7-methyladenosine, 3-
methylguanosine, 7-methylguanosine, 7-hydroxyethylguanosine, 7-chloroethyl-
guanosine, 02-alkylthymidine, 02-alkylcytidine, hypoxanthosine, 1,N6-etheno-
adenosine or 3,N4-ethenocytidine. E. coli endonuclease III (Biochem. J. 242
(1987) 565), as an alternative, separates the bases from 5-hydroxycytidine,
5,6-
dihydrothymidine, 5-hydroxy-5,6-dihydrothymidine, thymidine glycol, uridine-
glycol, alloxan, 5,6-dihydrouridine, 5-hydroxy-5,6-dihydrouridine or 5-hydroxy-
uridine. Endonuclease III has in addition to its DNA N-glycosylase activity an
AP
lyase activity which cleaves at the 3'-end bond of an AP site via f3-
elimination
(Nucl. Acid. Res. 16 (1988) 1135). Thus the treatment of a nucleic acid
molecule
containing the aforementioned substrate residues for endonuclease III leads to
nicks with' a a,f3-unsaturated aldehyde (>irans-4-hydroxy-2-pentenal-5-phos-
phate) at the 3'-end and a phosphate group at the 5'-end.
In another particularly preferred embodiment, when DNA is the nucleic acid and
one or more rNTPs are used as marker nucleotides, the rNMP residues incorpo-
rated in a DNA double strand can be recognized by a ribonuclease H (RNase H,
Figure 5). Preferably, RNase H1 from K562 human erythroleukemia cells is used,
that cleaves at the 5'-site of an RNA segment in the DNA strand consisting of
one
or more ribonucleotide residues (J. Biol. Chem. 266 (1991) 6472). This
reaction
leads to a nick with a S'-p-rNMP residue at one side and a free 3'-OH group at
the other side. Alternatively, other RNases H can be employed, e.g. E. coli
RNase
H or the RNase H activity of reverse transcriptases. The reaction can be
started
e.g. by changing the buffer conditions or the temperature or by adding the en-
zyme and can be stopped, for instance, by changing the buffer conditions or
temperature or by adding an inhibitor.
In a preferred embodiment the AP site resulting from the action of a DNA N-gly-
cosylase is cleaved by a class II AP endonuclease (Figure 2). In particular,
En-
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
donuclease IV (J. Biol. Chem. 252 (1977) 2808) or Exonuclease III (). Biol.
Chem., 239 (1964) 242) can be used for this reaction. The incubation of a
polynucleotide molecule containing AP sites with these enzymes leads via hy-
drolysis to a nick with a 5'-deoxyribosephosphate (dRp) group at one side and
a
free 3'-OH group at the other side (Nucl. Acid. Res. 18 (1990) 5069).
In a particularly preferred embodiment the 5'-dRp group resulting from the ac-
tion of a class II AP endonuclease is cleaved by an enzyme showing deoxyribose-
phosphatase activity (dRpasen). For this reaction, a multitude of enzymes can
be.
employed. For example: E. coli exonuclease I (Nucl. Acid. Res. 20 (1992)
4699),
E. coli RecJ protein (Nucl. Acid. Res. 22, 1994, 993); E. coli endonuclease
III
(Nucl. Acid. Res. 17, 1989, 6269); E. coli formamidopyrimidine-DNA glycosylase
(Fpg, J. Biol. Chem. 267, 1992, 14429); E. coli endonuclease VIII (J. Biol.
Chem.
272, 1997, 32230); T4 endonuclease V (Biochemistry 32, 1993, 8284); T4 DNA
ligase (J. Biol. Chem. 273, 1998, 7888); T7 DNA ligase (J. Biol. Chem. 273,
1998, 7888) or DNA polymerise I, T7 DNA polymerise and MMLV reverse tran-
scriptase (J. Biol. Chem. 275, 2000, 12509).
In another preferred embodiment the AP site resulting from the action of a DNA
N-glycosylase is cleaved by a class I AP endonuclease (Figure 3). For this
reac-
tion, E. coli endonuclease III (.Biochem. J. 242, 1987, 565-573) or T4
endonucle-
ase V (Mutat. Res. 459, 2000, 43-53) can be employed. The incubation of a
polynucleotide molecule containing AP sites with these enzymes leads via f3-
elimination to a nick with a a,f3-unsaturated aldehyde (traps-4-hydroxy-2-pen-
tenal-5-phosphate) at the 3'-end and a phosphate group at the 5'-end (FEBS
Lett. 178, 1984, 223; Nucl. Acid. Res. 16, 1988, 1135). The 3'-aldehyde has to
be removed by a class II AP endonuclease such as exonuclease III or endonucle-
ase IV (Biochem. J. 242, 1987, 565) resulting in a free 3'-OH group.
In a preferred embodiment the AP site resulting from the action of a DNA N-gly-
cosylase is cleaved by an AP lyase which cleaves at the AP site via a a,f3-
elimina-
tion (Figure 4). E. coli endonuclease VIII (J. Biol. Chem. 272, 1997, 32230)
and
E. coli formamidopyrimidine-DNA glycosylase (Fpg, J. Biol. Chem. 267, 1992,
14429) can be employed for this purpose. The incubation of a DNA double strand
containing AP sites with these enzymes leads to gap of one nucleotide with a
3'-
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
21
phosphate residue at one side of the gap and a 5'-phosphate residue at the
other
side of the gap. Afterwards, the 3'-phosphate group is removed by a class II
AP
endonuclease, as for example Exonuclease III or Endonuclease IV (J. Biol.
Chem.
258, 1983, 15198) or by T4 polynucleotide kinase (Biochemistry 16, 1977, 51-
20)
resulting in a free 3'-OH group.
In another preferred embodiment the marker strand consisting of DNA and con-
taining rNMP residues is cleaved by alkaline hydrolysis. This reactions leads
to a
nick with a 2'- or 3'-rNMP at the 3'-end and an OH group at the 5'-end. The re-
action can be started and stopped by changing the pH.
In another preferred embodiment the 2'- or 3'-rNMP at the 3'-end of a nick re-
sulting from the alkaline hydrolysis of a DNA polynucleotide containing rNMPs
is
removed by a class II AP endonuclease. Preferably, Exonuclease III or Endonu-
clease IV are used, resulting in a free 3'-OH group.,
According to step (4), the free 3'-OH group at a nick or gap resulting from
one or
more of the aforementioned reactions is extended with a template directed poly-
merise reaction with or without the incorporation of additional marker nucleo-
tides.
In a preferred embodiment the remaining part of the marker strand 3' of the
sin-
gle strand break, in particular strands containing a 5'-dRp group resulting
from
the action of a class II AP endonuclease, are bound with a surplus of the
corre-
sponding complementary strands and are thereby removed from the template
strand. Then, any kind of polymerise can be employed to extend the 3'-OH
group by template-directed polymerization.
In another preferred embodiment the remaining part of the marker strand 3' of
the single strand break is removed from the template strand by employing a po-
lymerise showing strong strand displacement properties. Preferably, Vent DNA
polymerise or Klenow DNA polymerise are employed for this purpose.
In another preferred embodiment the remaining part of the marker strand 3' of
the single strand break is removed from the template strand by a 5'-
exonuclease
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
22
activity. For this purpose, any polymerise showing a 5'-exonuclease activity
can
be employed. Preferably, Taq DNA polymerise or Tth DNA polymerise are used.
Alternatively, 5'-3' exonucleases can be used in combination with any poly-
merise. Then, preferably, Lambda Exonuclease (Gene Amplification and Analysis
2,1981, 135) or T7 Exonuclease (Nucl. Acid. Res. 5, 1978, 4245) are used.
Embodiment (B) of the invention relates to a kit containing instructions for
car-
rying out the method embodiment (A) of the invention. Preferably, said kit con-
tains the following components:
(i) marker nucleotides for incorporation in the polynucleotide molecules;
(ii) agents permitting the single-stranded breaks at the incorporated marker
nucleotides; and
(i1i) buffers for carrying out the incorporation of the marker nucleotides and
producing the single-stranded breaks.
The kit may contain further components, e.g. one or more of the following:
(iv) a buffer for producing double-stranded polynucleotides;
(v) agents permitting the template-directed polymerization of a polynucleo-
tide strand starting form the single-stranded break; and
(vi) buffer for carrying out the polymerization reaction.
The invention is further explained by the following examples, which are,
however,
not to be construed to limit the invention.
Exa m pies
Example 1 : Generating single recombination events per gene that are randomly
distributed
1. Provide partially homologous and heterologous genes to be recombined.
Amplify the genes by PCR introducing an Eco RI restriction site at the one
end and a Hind III restriction site at the other end.
2. Incubate 1 pg of each PCR product and 1 Ng of pUCl8 vector with 1 U Eco
RI (e.g. NEB) and 1 U Hind III (e.g. NEB) in Eco RI reaction buffer (100 mM
Tris-HCI, pH 7.5; 50 mM NaCI; 10 mM MgCl2; 0.025 % (v/v) Triton~ X-100)
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
23
for 2 h at 37 °C. Heat inactivate the enzymes for 20 min at 65
°C. Purify the
cleavage products e.g. with QiaQuick (Qiagen).
3. Ligate the PCR products into the pUCl8 vector using 200 fmol vector, 600
fmol insert, 1 p1 of lOX Ligation Buffer (500 mM Tris-HCI, pH 7.5; 100 mM
MgCl2; 100 mM DTT; 10 mM ATP, 250 Ng/ml BSA), 5 Weiss Unit of T4 DNA
ligase (e.g. NEB) ad 10 p1 aqua dest. Incubate 1 h at room temperature and
heat inactivate the enzyme for 10 min at 65 °C. Transform E, coli XL1-
Blue
with the ligated vector, e.g. by electroporation. Make plasmid preparations
from positive clones using e.g. Qiagen Mini Plasmid Prep Kits.
4. Amplify the inserted genes with a PCR using the primers:
pUC-left: 5'-CCAGTCACGACGTTGTAAAACG-3' (SEQ ID NO:1)
pUC-right: 5'-TAACAATTTCACACAGGAAACAGC-3' (SEQ ID N0:2)
by mixing 10 p1 lOX PCR buffer (200 mM Tris-HCI, pH 8.75; 100 mM KCI;
100 mM (NH4)z 504; 20 mM MgClz; 1 % (v/v) Triton~ X-100; 1 mg/ml BSA),
fmol template vector, 100 pmol pUC-left, 100 pmol pUC-right, 200 NM
dNTPs, 2 U Pfu DNA polymerase (e.g. Stratagene) ad 100 p1 aqua dest. and
using the following cycler protocol: 1' 94 °C; 30 cycles consisting of
1' 94
°C, 1' 50 °C, 1.5' 72 °C; 2' 72 °C. Purify the PCR
products, e.g. with
QiaQuick~.
5. Make a set of asymmetric PCRs with the mixed PCR-products as templates
varying the added dUTP concentration (e.g. 0.2 NM; 1 NM; 5 NM; 25 pM;
100 pM dUTP) by mixing 10 p1 10X PCR buffer (100 mM Tris-HCI, pH 8.3;
500 mM KCI; 15 mM MgClz; 0.01 % (w/v) gelantin), 1' pmol template DNA,
100 pmol pUC-left, 100 pmol blocked pUC-right (3'-NH2 modification), 200
NM dNTPs, any of the above mentioned dUTP concentrations, 2 U Taq DNA
polymerase (e.g. Applied Biosystems) ad 100 NI aqua dest., and using the
following cycler protocol: 1' 94 °C; 30 cycles consisting of 1' 94
°C, 1' S0
°C, 1.5' 72 °C. Purify the PCR products, e.g. with QiaQuick~
(Qiagen) and
pool the PCR-products as marker strands.
Make an asymmetric PCR with the mixed PCR-products as template (anti-
sense strand) by mixing 10 NI 10X PCR buffer (100 mM Tris-HCI, pH 8.3;
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
24
500 mM KCI; 15 mM MgCl2; 0.01 % (w/v) gelantin), 1 pmol template DNA,
100 pmol blocked pUC-left (3'-NHZ modification), 100 pmol pUC-right, 200
NM dNTPs, 2 U Taq DNA polymerise (e.9. Applied Biosystems) ad 100 NI
aqua dest., and using the following cycler protocol: 1' 94 °C; 30
cycles con-
sisting of 1' 94 °C, 1' S0 °C, 1.5' 72 °C. Purify the PCR
products, e.g. with
QiaQuick~ (Qiagen) and pool the PCR-products as template strands.
6. Anneal 2 pmol of sense strand (with incorporated dU ~s) and 2 pmol of anti-
sense strand in 100 mM NaCI (2' 95 °C, 95 °C -> 50 °C
with 0,04 °C/s).
Purify the annealed double stranded DNA, e.g. with QiaQuick~-Kit
7. Incubate 2 pmol of the annealed double stranded DNA with 1 U UDG (e.g.
NEB) and 2 U Endonuclease IV (e.g. Epicentre) 1h at 37 °C in 20 NI
UDG-
Puffer (20 mM Tris-HCI, pH 8.0; 1 mM EDTA; 1 mM DTT). Add 80 NI of Vent-
buffer (20 mM Tris-HCI, pH 8.8; 10 mM KCI; 10 mM (NH4)ZS04; 2 mM
MgS04; 0.1 % (v/v) Triton~ X-100), 200 NM dNTPs and 2 U Vent(exo-) DNA
polymerise (NEB). Incubate 5 min at 72 °C. Purify the DNA with
QiaQuick~
(Qiagen).
8. Incubate the product and 1 pg of pUCl8 vector each with 1 U Eco RI (e.g.
NEB) and 1 U Hind III (e.g. NEB) in Eco RI reaction buffer (100 mM Tris-
HCI, pH 7.5; 50 mM NaCI; 10 mM MgCl2; 0.025 % (v/v) Triton~ X-100) for 2
h at 37 °C. Heat inactivate the enzymes for 20 min at 65 °C.
Purify the
cleavage products e.g. with QiaQuick~-Kit. ).
9. Ligate the product into the pUCl8 vector using: 200 fmol vector, 600 fmol
insert, 1 NI of lOX Ligation Buffer (500 mM Tris-HCI, pH 7.5; 100 mM MgCl2;
100 mM DTT; 10 mM ATP, 250 pg/ml BSA), 5 Weiss Unit of T4 DNA ligase
(e.g. NEB) ad 10 p1 aqua dest. Incubate 1 h at room temperature and heat
inactivate the enzyme for 10 min at 65 °C. Transform E, coli XL1-Blue
with
the ligated vector.
Example 2: Generating more than one recombination event per gene
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
For steps 1. to 4. see Example 1.
5. Make an asymmetric PCR with the mixed PCR-products as template by
mixing.10 p1 lOX PCR buffer (100 mM Tris-HCI, pH 8.3; 500 mM KCI; 15 mM
MgCl2; 0.01 % (w/v) gelantin), 1 pmol template DNA, 100 pmol pUC-left,
100 pmol locked pUC-right (3'-NHz modification), 200 NM dNTPs, 2 pM
dUTP, 2 U Taq DNA polymerase (e.g. Applied Biosystems) ad 100 p1 aqua
dest., and using the following cycler protocol: 1' 94 °C; 30 cycles
consisting
of 1' 94 °C, 1' S0 °C, 1.5' 72 °C. Purify the PCR
products, e.g. with QiaQuick
~ (Qiagen) as marker strands.
Make an asymmetric PCR with the mixed PCR-products as template by
mixing 10 NI 10X PCR buffer (100 mM Tris-HCI, pH 8.3; 500 mM KCI; 15 mM
MgCIZ; 0.01 % (w/v) gelantin), 1 pmol template DNA, 100 pmol blocked
pUC-left (3'-NH2 modification), 100 pmol pUC-right, 200 NM dNTPs, 2 U Taq
DNA polymerase (e.g. Applied Biosystems) ad 100 NI aqua dest., and using
the following cycler protocol: 1' 94 °C; 30 cycles consisting of 1' 94
°C, 1'
50 °C, 1.5' 72 °C. Purify the PCR products, e.g. with QiaQuick~
(Qiagen) as
template strands.
6. Anneal 2 pmol of marker strand (with incorporated dU ~s) and 2 pmol of
template strand in 100 mM NaCI (2' 95 °C, 95 °C -> 50 °C
with 0,04 °C/s).
Purify the annealed double stranded DNA, e.g. with QiaQuick~-Kit (Qiagen).
7. Incubate 2 pmol of the annealed double stranded DNA with 1 U UDG (e.g.
NEB) and 2 U Endonuclease IV (e.g. Epicentre) 1h at 37 °C in 20 NI
UDG-
Puffer (20 mM Tris-HCI, pH 8.0; 1 mM EDTA; 1 mM DTT). Add 2 U of UGI
(Uracil Glycosylase Inhibitor, e.g. NEB). Add 80 p1 of Vent-buffer (20 mM
Tris-HCI, pH 8.8; 10 mM KCI; 10 mM (NH4)ZS04; 2 mM MgS04; 0.1 % (v/v)
Triton~ X-100), 200 NM dNTPs, 2 NM dUTP and 2 U Vent(exo-) DNA poly-
merase (NEB). Incubate 5 min at 72 °C. Purify the DNA (e.g. with
QiaQuick~).
8. Reaneal the various strands in 100 mM NaCI (2' 95 °C, 95 °C -
> 50 °C with
0,04 °C/s).
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
26
9. Repeat steps 7 and 8 several times (the number of cycles should equal the
length of gene in by / 100).
10. Incubate the product and 1 Ng of pUCl8 vector each with 1 U Eco RI (e.g.
NEB) and 1 U Hind III (e.g. NEB) in Eco RI reaction buffer (100 mM Tris-
HCI, pH 7.5; 50 mM NaCI; 10 mM MgClz; 0.025 % (v/v) Triton~ X-100) for 2
h at 37 °C. Heat inactivate. the enzymes for 20 min at 65 °C.
Purify the
cleavage products e.g. with QiaQuick~-Kit.
ll. Ligate the product into the pUCl8 vector using: 200 fmol vector, 600 fmol
insert, 1 NI of 10X Ligation Buffer (500 mM Tris-HCI, pH 7.5; 100 mM MgClz;
100 mM DTT; 10 mM ATP, 250 Ng/ml BSA), 5 Weiss Unit of T4 DNA ligase
(e.g. NEB) ad 10 p1 aqua dest. Incubate 1 h at room temperature and heat
inactivate the enzyme for 10 min at 65 °C. Transform E. coli XL1-Blue
with
the ligated vector.
Example 3: Generating randomly recombined subtilisin genes
Four partially homologous and partially heterologous subtilisin genes were
recombined according to the method of the invention as follows. The four genes
were the wild type gene and three mutants, variant 15, variant 21, and variant
22, from the gene aprE coding for Subtilisin E from B. subtilis (see Figure 7
and
SEQ ID N0:5 showing the amino acid sequence of the aprE encoded subtilisin E -
protein).
1. Each of the four partially homologous and partially heterologous genes was
PCR-amplified using the primers:
PrimerHL: 5'-CGTTGCATATGTGGAAGAAGATC-3 ~ (SEQ ID N0:3)
PrimerHR: 5'-GAAGCAGGTATGGAGGAAC-3' (SEQ ID N0:4)
PCR was performed by mixing 10 NI 10x PCR buffer (200 mM Tris-HCI, pH
8.8; 100 mM KCI; 100 mM (NH4)zS04; 25 mM MgS04; 1 % (v/v) Triton~~ X-
100; 1 mg/ml BSA), 10 fmol template, 100 pmol PrimerHL,100 pmol
PrimerHR, 200 pM dNTPs, 2.5 U Taq DNA polymerase (MBI Fermentas), ad
100 NI aqua dest, using the following thermal cycler protocol: 1' 94
°C; 25
cycles consisting of 1' 94 °C, 1' S5 °C, 1.5' 72 °C; 2'
72 °C. PCR products
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
27
were purified with the QiaQuick~ PCR purification kit (Qiagen, Hilden,
Germany).
2. In a second PCR, each of the four genes was PCR-amplified under
incorporation of the marker nucleotide using the same primers as in step 1.
PCR was performed by mixing 200 NM of a dNTP mix where dTTP is reduced
and replenished by dUTP to result in a ratio of dUTP/dTTP of 1:40, with 10 p1
10x PCR buffer (750 mM Tris-HCI, pH 8.8; 200 mM (NH4)2S04; 25 mM MgClz;
0.1 % (v/v) Tween~ 20); 2.5 U Taq DNA polymerise (MBI Fermentas) ad 100
p1 aqua dest, using the following thermal cycler protocol: 1' 94 °C; 25
cycles
consisting of 1' 94 °C, 1' 52 °C, 1.5' 72 °C. PCR
products were purified with
the QiaQuick~ PCR purification kit (Qiagen, Hilden, Germany).
3. A 1:1 mixture of marker-incorporated to marker-free polynucleotides was
made by mixing 0.5 ug (approx. 1 pmol) of each PCR product of step 2
(marker incorporated) and 0.5 p9 (approx. 1 pmol) of each PCR product of
step 1 (marker-free) in 100 mM NaCI. Produce heteroduplex molecules by
heating for 2' at 94 °C, and cooling down to 50 °C with a rate
of 0.04 °C/s).
Analogously, 1:3 and 1:9 mixtures of marker-incorporated to marker-free
polynucleotides were made by mixing corresponding amounts of PCR
products from step 2 and 1, and producing heteroduplex molecules by the
same protocol.
4. 2 pg (approx. 3.8 pmol) of each of the heteroduplex molecule mixtures was
incubated for 30 min at 37 °C with 1 U UDG (NEB) in 20 p1 lx UDG-buffer
(20 mM Tris-HCI, pH 8.0; 1 mM EDTA; 1 mM DTT). 2 U Endonuclease IV
(Epicentre) were added, the reaction volume was increased to 20 p1 with lx
UDG-buffer, and the mixtures were incubated for additional 30 min at 37
°C.
Then, 80 NI Taq-buffer (750 mM Tris-HCI, pH 8.8; 200 mM (NH4)ZS04; 0,1
Tween 20), 200 pM dNTPs, and 2.5 U Taq DNA Polymerise (MBI Fermentas)
were added, and the mixtures were incubated for additional 5 min at
72°C.
Products were purified with the QiaQuick~ PCR purification kit (Qiagen,
Hilden, Germany).
5. Polynucleotides were resuspended in 100 mM NaCI, and again, heteroduplex
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
28
molecules were produced by melting strands through heating for 2' at 94
°C,
and cooling down to 50 °C with a rate of 0.04 °C/s).
6. Steps 4 and 5 were repeated two times.
7. Finally, in order to separate heteroduplex strands, 20 pmol of PrimerML and
PrimerMR were added to each mixture, and 3 cycles PCR using the cycler
protocol: 1' 94 °C, 1' 52 °C, 1.5' 72 °C were performed.
Recombined
polynucleotides were purified using the QiaQuick~ PCR purification kit
(Qiagen, Hilden, Germany).
8. Recombined polynucleotides were then ligated into the vector pBVP43 (see
Figure 7) behind the P43 promotor with the vector being constructed as
follows: The pMB1 origin from pUCl9 (ATCC 37254) was PCR amplified
(positions 763 - 1601) and introduced into the PvuII site of pUB110 (ATCC
37015). The fragment between SapI and BgIII was removed from this vector.
Then, an insert containing the P43 promoter from the cdd gene of B. subtilis,
the signal sequence and the terminator from the subtilisin E gene of B.
subtilis, as well as a short multiple cloning site between the signal sequence
and the terminator was introduced into the unique SphI site, resulting in the
vector pBVP43empty. The wild type subtilisin E gene (coding for the protein
of SEQ ID N0:5 and being derivable from the genome of Bacillus subtilis
strain 168 (DSM #402)) without the signal sequence as well as any other
subtilisin variant was introduced in frame with the signal sequence into the
multiple cloning site resulting in the vector pBVP43.
9. Recombined polynucleotides were then ligated into the vector pBVP43 (see
Figure 7) behind the P43 promotor. Ligation was done using 300 fmol vector,
1500 fmol insert, 2 NI of 10x Ligation buffer (500 mM Tris-HCI, pH 7.5; 100
mM MgCl2; 100 mM DTT; 10 mM ATP, 250 Ng/ml BSA), 5 Weiss Units of T4
DNA ligase (MBI Fermentas), ad 20 NI aqua dest, by incubation for 2 h at
room temperature, followed by heat inactivation for 10 min at 65 °C,
and
ethanol precipitation. The ligation mixture was then transformed into
electrocompetent E. coli XL1-Blue.
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
29
lO.Isolated clones were sequenced in order to determine the number of
recombinants and the frequency of recombination events.
Results from the sequence analysis of a representative set of clones are shown
in
Figure 8. which shows a comparison of amino acid residues of the starting
material of the wild type subtilisin and' three mutants thereof and those of
the
recombinants obtained by the use of the method of this invention. The amino
acids are abbreviated as shown in Table I below.
Overall, 17 out of 26 clones were recombined corresponding to 65
recombinants. The average number of recombination events per gene over all
clones was approximately 1.2.
As shown in Figure 9, the ratio of marker-free to marker-incorporated PCR
products of 1:1 and 1:3 showed approximately 75 % recombinants (Figure 9B);
the recombinants resulting of the _ 1:3 mixture had on average 1.50
recombination events in comparison to the 1:1 mixture (Figure 9A).
Table I: Amino acid abbreviations
Abbreviations Amino acid
A Ala Alanin
C C s C steine
D As As artic acid
E Glu Glutamic acid
F Phe Phen lalanine
G GI GI cine
H His Histidine
I Ile Isoleucine
K L s L sine
L Leu Leucine
M Met Methionine
N Asn As ara ine
P Pro Proline
Gln Glutamine
R Ar Ar inine
S Ser Serine
T Thr Threonine
V Val Valine
W Tr Tr to hane
Y T r T cosine
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
1/2
SEQUENCE LISTING
<110> DIREVO Biotech AG
<120> Method for the Production of Nucleic Acids Consisting
of Stochastically Combined Parts of Source Nucleic
Acids
<130> 021880wo/JH/BM/ml
<140>
<141>
<160> 5
<170> PatentIn Ver. 2.1
<210> 1
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Primer
pUC-Left
<400> 1
ccagtcacga cgttgtaaaa cg 22
<210> 2
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Primer
pUC-Right
<400> 2
taacaatttc acacaggaaa cagc 24
<210> 3
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: PrimerHL
<400> 3
cgttgcatat gtggaagaag atc 23
<210> 4
<211> 19
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: PrimerHR
<400> 4
gaagcaggta tggaggaac 19
CA 02455325 2004-O1-27
WO 03/012100 PCT/EP02/08122
2/2
<210> 5
<211> 275
<212> PRT y.
<213> Bacillus subtilis
<400> 5
Ala Gln Ser Val Pro Tyr Gly Ile Ser Gln Ile Lys Ala Pro Ala Leu
1 5 10 15
His Ser Gln Gly Tyr Thr Gly Ser Asn Val Lys Val Ala Val Ile Asp
20 25 30
Ser Gly Ile Asp Ser Ser His Pro Asp Leu Asn Val Arg Gly Gly Ala
35 40 45
Ser Phe Val Pro Ser Glu Thr Asn Pro Tyr Gln Asp Gly Ser Ser His
50 55 60
Gly Thr His Val Ala Gly Thr Ile Ala Ala Leu Asn Asn Ser Ile Gly
65 70 75 80
Val Leu Gly Val Ser Pro Ser Ala Ser Leu Tyr Ala Val Lys Val Leu
85 90 95
Asp Ser Thr Gly Ser Gly Gln Tyr Ser Trp Ile Ile Asn Gly Ile Glu
100 105 110
Trp Ala Ile Ser Asn Asn Met Asp Val Ile Asn Met Ser Leu Gly Gly
115 120 125
Pro Thr Gly Ser Thr Ala Leu Lys Thr Val Val Asp Lys Ala Val Ser
130 135 140
Ser Gly Ile Val Val Ala Ala Ala Ala Gly Asn Glu Gly Ser Ser Gly
145 150 155 160
Ser Thr Ser Thr Val Gly Tyr Pro Ala Lys Tyr, Pro Ser Thr Ile Ala
165 170 175
Val Gly Ala Val Asn Ser Ser Asn Gln Arg Ala Ser Phe Ser Ser Ala
180 185 190
Gly Ser Glu Leu Asp Val Met Ala Pro Gly Val Ser Ile Gln Ser Thr
195 200 205
Leu Pro Gly Gly Thr Tyr Gly Ala Tyr Asn Gly Thr Ser Met Ala Thr
210 215 220
Pro His Val Ala Gly Ala Ala Ala Leu Ile Leu Ser Lys His Pro Thr
225 230' 235 240
Trp Thr Asn Ala Gln Val Arg Asp Arg Leu Glu Ser Thr Ala Thr Tyr
245 250 255
Leu Gly Asn Ser Phe Tyr Tyr Gly Lys Gly Leu Ile Asn Val Gln Ala
260 265 270
Ala Ala Gln
275
